MStranslate

Providing accurate, unbiased, easy to understand information about multiple sclerosis research and news worldwide. #MultipleSclerosis #MS

[MStranslate @MStranslate]

By uncovering how the immune system supports myelin repair, researchers are identifying new ways to enhance remyelination. As these therapies continue to advance, understanding why this process becomes less efficient with ageing may be key to maximising their benefits. [2/2]

[MStranslate @MStranslate]

One of the major challenges in #MultipleSclerosis is that the brain’s ability to repair damaged myelin declines with age. That’s why research like this from @QUBelfast is so important. [1/2] https://t.co/aDuhODIRm7

[MStranslate @MStranslate]

In recognition of #WorldMSDay today, our co-founder, Brett Drummond, took to Facebook Live to connect with our community & express appreciation to everyone that has supported & contributed to our journey across the years. #MultipleSclerosis #MS https://t.co/6BBQuNNOyA

[MStranslate @MStranslate]

We congratulate @MS_Australia on their involvement in this program and look forward to seeing its impact and outcomes in the years ahead. [2/2]

[MStranslate @MStranslate]

It’s encouraging to see people living with #MultipleSclerosis increasingly involved in conversations about #MS research, especially in regard to progressive MS where many significant unmet needs remain. [1/2] https://t.co/gB0Ne4Vra6

[MStranslate @MStranslate]

As this remains an area of significant unmet need, we’ll be following developments with great interest. Learn more: https://t.co/XoBrng0AfK [2/2]

[MStranslate @MStranslate]

A new @JohnsHopkins trial, TAG-MS, is exploring if pegsebrenatide can slow neurodegeneration in those living with #MultipleSclerosis. This treatment targets the GLP-1 receptor & early evidence suggests this class of drugs may have protective effects within the brain & CNS. [1/2]

[MStranslate @MStranslate]

As #MS can vary so much from person to person, there’s growing interest in using such insights to help predict how the disease might develop over time. While it’s still early, the hope is that this approach could lead to more personalised management decisions in the future. [2/2]

[MStranslate @MStranslate]

Big data is starting to change how researchers understand #MultipleSclerosis. By analysing large amounts of information from many people, like MRI scans, symptoms & treatment outcomes, scientists are beginning to spot patterns in how the disease progresses. [1/2]

[MStranslate @MStranslate]

While these principles have been designed for implementation in the UK system, many of them are applicable around the world. [2/2]

[MStranslate @MStranslate]

The @mssocietyuk have published a new report highlighting the importance of improving access to #rehabilitation services for people living with #MultipleSclerosis, outlining ten key principles that need to change. #MS https://t.co/sSANjxYPvu [1/2]

[MStranslate @MStranslate]

This follows a decision late in 2025 by the @US_FDA to delay approval, requesting more data from @sanofi on who is most likely to benefit. We will continue to monitor these developments & provide updates as they become available.

[MStranslate @MStranslate]

Exciting news for people living with secondary progressive #MultipleSclerosis without relapses - the European Medicines Agency is expected to approve #tolebrutinib as a new treatment option. #MS @EMA_News

[MStranslate @MStranslate]

A key #MultipleSclerosis research focus is understanding why the condition disproportionately affects women. A new @CUAnschutz study has identified specific proteins that may help explain this disparity & could pave the way for new therapeutic approaches. https://t.co/0Op2MciJ7h

[ECTRIMS @ECTRIMS]

🚨 New Podcast Episode
Phase 3 FENhance data released at #AAN show fenebrutinib significantly reduces relapse activity in #MS comapred to teriflunomide

🎧 𝐇𝐞𝐚𝐫 𝐭𝐡𝐞 𝐞𝐱𝐩𝐞𝐫𝐭𝐬:
Spotify https://t.co/nZxtAHlw8G
Apple: https://t.co/MCu2jloRZi
Website: https://t.co/l53dGqkANT

#MultipleSclerosis #MSResearch #BTKi #ECTRIMSPodcast

[MStranslate @MStranslate]

Did you know there’s an organisation conducting studies to determine the best #rehabilitation strategies for people living with #MultipleSclerosis? It’s known as @eurims & you can learn more about it in this recent episode of The @ECTRIMS Podcast. #MS https://t.co/Zmol8NVzjh

[MStranslate @MStranslate]

If you’re comfortable sharing, please comment with more detail about your situation, especially if there are particular rehabilitation activities that have delivered real benefits.

[MStranslate @MStranslate]

VOTE NOW: Do you currently have a structured #rehabilitation plan as part of your #MultipleSclerosis management strategy?

*AHP below stands for Allied Health Professional, i.e. a physiotherapist.

[MStranslate @MStranslate]

We recently participated in @MS_Auckland’s webinar on myelin repair research in #MultipleSclerosis, alongside Dr Nick Cunniffe (@Cambridge_Uni) who led the CCMR Two trial investigating the remyelination potential of metformin & clemastine. Watch it below. https://t.co/NOdRTOwHU8

[MStranslate @MStranslate]

@MSViewsandNews @MS_Auckland @Cambridge_Uni Thank you for your interest! A full recording of the discussion is now available on the @MS_Auckland YouTube channel. If you have any questions after watching, please don’t hesitate to ask them here & we’ll reply asap. https://t.co/FBWbhNlO0H

[MStranslate @MStranslate]

In just over 6 hrs, our co-founder, Brett Drummond, will be joining a FREE Remyelination Research in #MultipleSclerosis webinar, hosted by @MS_Auckland. Excitingly, adding his wealth of experience & expertise to this discussion will be Dr Nicholas Cunniffe, @Cambridge_Uni.